Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04371367 | Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE ) | PHASE2 | COMPLETED | 208 | — | — | Apr 27, 2020 | Mar 30, 2021 | May 27, 2021 | 1 | France |
improvement of WHO ordinal scale
Number of days without mechanical ventilation at Day 28 for COVID-19 related Acute Respiratory Distress Syndrome (ARDS) Patients hospitalized in ICU
| Arm | Type | Description |
|---|---|---|
| avdoralimab | EXPERIMENTAL | Biological/Vaccine: avdoralimab intravenous administration of avdoralimab Other Names: • IPH5401 |
| Placebo | PLACEBO_COMPARATOR | intravenous administration of Placebo |
| Name | Type | Description |
|---|---|---|
| avdoralimab | BIOLOGICAL | intravenous administration of avdoralimab |
| Placebo | OTHER | intravenous administration of placebo |
Inclusion Criteria: * COVID-19 severe pneumonia patients need for oxygen therapy ≥ 5 l/min or high-flow oxygen therapy * COVID-19 related Acute Respiratory Distress Syndrome (ARDS) requiring mechanical ventilation Exclusion Criteria: * Pregnant woman * Uncontrolled sepsis of bacterial or fungal o...